MA43793A - Procédé de préparation de formulations solides de mésalazine - Google Patents

Procédé de préparation de formulations solides de mésalazine

Info

Publication number
MA43793A
MA43793A MA043793A MA43793A MA43793A MA 43793 A MA43793 A MA 43793A MA 043793 A MA043793 A MA 043793A MA 43793 A MA43793 A MA 43793A MA 43793 A MA43793 A MA 43793A
Authority
MA
Morocco
Prior art keywords
mesalazine
solid formulations
preparing solid
preparing
formulations
Prior art date
Application number
MA043793A
Other languages
English (en)
Other versions
MA43793B1 (fr
Inventor
Carla Labruzzo
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56551461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MA43793A publication Critical patent/MA43793A/fr
Publication of MA43793B1 publication Critical patent/MA43793B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
MA43793A 2016-04-05 2017-04-04 Procédé de préparation de formulations solides de mésalazine MA43793B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A002293A ITUA20162293A1 (it) 2016-04-05 2016-04-05 Processo per formulazioni solide di mesalazina
PCT/IB2017/051907 WO2017175123A1 (fr) 2016-04-05 2017-04-04 Procédé de préparation de formulations solides de mésalazine

Publications (2)

Publication Number Publication Date
MA43793A true MA43793A (fr) 2018-11-28
MA43793B1 MA43793B1 (fr) 2022-09-30

Family

ID=56551461

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43793A MA43793B1 (fr) 2016-04-05 2017-04-04 Procédé de préparation de formulations solides de mésalazine

Country Status (21)

Country Link
US (2) US11504331B2 (fr)
EP (1) EP3439637B1 (fr)
CN (2) CN109069428A (fr)
AU (1) AU2017247783B2 (fr)
BR (1) BR112018070521A2 (fr)
CL (1) CL2018002765A1 (fr)
CO (1) CO2018010142A2 (fr)
DK (1) DK3439637T3 (fr)
ES (1) ES2924881T3 (fr)
HR (1) HRP20221073T1 (fr)
HU (1) HUE059531T2 (fr)
IT (1) ITUA20162293A1 (fr)
LT (1) LT3439637T (fr)
MA (1) MA43793B1 (fr)
MD (1) MD3439637T2 (fr)
MX (1) MX2018011685A (fr)
PL (1) PL3439637T3 (fr)
PT (1) PT3439637T (fr)
RS (1) RS63492B1 (fr)
SI (1) SI3439637T1 (fr)
WO (1) WO2017175123A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
EP0955376A4 (fr) 1996-11-25 2001-03-28 Takara Shuzo Co Antibiotique tkr 459, son procede de production et micro-organisme
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
MXPA04003506A (es) 2001-10-15 2004-07-23 Ferring Bv Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
US8282955B2 (en) * 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
US20090017110A1 (en) 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
EP2425826A1 (fr) 2010-09-01 2012-03-07 Disphar International B.V. Comprimé de mésalazine doté d'une dissolution améliorée
WO2012032185A1 (fr) 2010-09-10 2012-03-15 Pharmazell Gmbh Procédé de production d'acide 5-aminosalicylique cristallin
EP2468264A1 (fr) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Comprimé pharmaceutique oral pour la libération prolongée de mésalazine et son procédé de fabrication
EP3162362A1 (fr) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Comprimé optimisé a une haute dose contenant de la mesalazine
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
AR108231A1 (es) * 2016-04-19 2018-08-01 Ferring Bv Composiciones farmacéuticas orales de mesalazina

Also Published As

Publication number Publication date
CN109069428A (zh) 2018-12-21
MD3439637T2 (ro) 2022-10-31
ITUA20162293A1 (it) 2017-10-05
HUE059531T2 (hu) 2022-11-28
US20230104254A1 (en) 2023-04-06
US20190151245A1 (en) 2019-05-23
SI3439637T1 (sl) 2022-10-28
WO2017175123A1 (fr) 2017-10-12
HRP20221073T1 (hr) 2022-11-25
RS63492B1 (sr) 2022-09-30
CL2018002765A1 (es) 2019-01-18
DK3439637T3 (da) 2022-08-29
BR112018070521A2 (pt) 2019-01-29
MA43793B1 (fr) 2022-09-30
ES2924881T3 (es) 2022-10-11
MX2018011685A (es) 2018-12-19
EP3439637A1 (fr) 2019-02-13
PL3439637T3 (pl) 2022-09-26
AU2017247783B2 (en) 2022-12-22
US11504331B2 (en) 2022-11-22
PT3439637T (pt) 2022-08-30
EP3439637B1 (fr) 2022-06-01
LT3439637T (lt) 2022-09-12
AU2017247783A1 (en) 2018-10-25
CN117442562A (zh) 2024-01-26
CO2018010142A2 (es) 2018-10-22

Similar Documents

Publication Publication Date Title
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
IL248149A0 (en) Formulations of dilutable cannabinoids and processes for their preparation
IL247722A0 (en) Pharmaceutical preparations containing active medicinal compounds for the treatment of hematological cancers
IL247721A0 (en) Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors
MA52906A (fr) Procédé de préparation d'amg 416
MA43835A (fr) Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
DK3359522T3 (da) Proces til fremstilling af N-Boc-bifenylalaninol
DK3445743T3 (da) Prodrug af aminosyrederivat
MA47022A (fr) Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
MA42423A (fr) Procédé de préparation d'un revêtement
DK3356235T3 (da) Fremgangsmåde til dannelse af grupper af røgartikler
MA47409A (fr) Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
DK3495339T3 (da) Fremgangsmåde til fremstilling af reaktionsprodukt
MA42264A (fr) Procédé de préparation d'oltipraz
IL267279A (en) Pharmaceutical formulations of suvorexant
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
MA43793A (fr) Procédé de préparation de formulations solides de mésalazine
IL253824A0 (en) Pharmaceutical formulations of c1 esterase inhibitor
MA43126A (fr) Compositions pharmaceutiques de fumarate de diméthyle
DK3344048T3 (da) Fremgangsmåde til fremstilling af mejeripulver
DK2962574T3 (da) Proces til fremstillingen af lav-bakterie mælkeprodukter
FR3024729B1 (fr) Procede de preparation du trioxane
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
MA50371A (fr) Procédé de préparation de dérivés spiro
ZA201705329B (en) Pharmaceutical formulations of racecadotril